Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome.

doi:10.1182/blood.2021014472

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome.

Blood - 14 Apr 2022

Grob Tim, Al Hinai Adil S A, Sanders Mathijs A, Kavelaars François G, Rijken Melissa, Gradowska Patrycja L, Biemond Bart J, Breems Dimitri A, Maertens Johan, van Marwijk Kooy Marinus, Pabst Thomas, de Weerdt Okke, Ossenkoppele Gert J, van de Loosdrecht Arjan A, Huls Gerwin A, Cornelissen Jan J, Beverloo H Berna, Löwenberg Bob, Jongen-Lavrencic Mojca, Valk Peter J M

Abstract excerpt

Substantial heterogeneity within mutant TP53 acute myeloid leukemia (AML) and myelodysplastic syndrome with excess of blast (MDS-EB) precludes the exact assessment of prognostic impact for individual patients. We performed in-depth clinical and molecular analysis of mutant TP53 AML and MDS-EB to dissect the molecular characteristics in detail and determine its impact on survival. We performed next-generation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cancer Genomics and Diagnostics

Share to Cytogenetics

Share to Leukemia, Myeloid, Acute

Share to Multiple Myeloma Research and Treatments

Share to Mutation

Share to Myelodysplastic Syndromes

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 35108372
DOI: 10.1182/blood.2021014472
PMCID: PMC11022827

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome.PMID 35108372Read ↗

Molecular characterization and prognosis of mutant TP53 acute myeloid leukemia and myelodysplastic syndrome with excess blasts.Semantic proximity Read ↗

Diagnosis and Classification of Myelodysplastic Syndromes with Mutated TP53.Semantic proximity Read ↗

Comparison of TP53 mutations in myelodysplasia and acute leukemia suggests divergent roles in initiation and progressionSemantic proximity Read ↗

Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes.Semantic proximity Read ↗

Current State and Future Prospects of Diagnosis and Management of TP53-Mutated Myeloid Neoplasms.Semantic proximity Read ↗

TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.Semantic proximity Read ↗

TP53 Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge?Semantic proximity Read ↗

Acute Myeloid Leukemia and Myelodysplastic Syndromes with TP53 Aberrations - A Distinct Stem Cell Disorder.Semantic proximity Read ↗

TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions.Semantic proximity Read ↗

Molecular characterization of AML-MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC-defining criteria, TP53 allelic state, or TP53 variant allele frequency.Semantic proximity Read ↗

Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutationsSemantic proximity Read ↗

A line in shifting sand: Can we define and target TP53 mutated MDS?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.